|
KR101137572B1
(ko)
*
|
2003-06-11 |
2012-05-30 |
이데라 파마슈티칼즈, 인코포레이티드 |
안정화된 면역조절 올리고뉴클레오티드
|
|
EP1648913A4
(en)
*
|
2003-07-15 |
2008-09-10 |
Idera Pharmaceuticals Inc |
SYNERGISTIC STIMULATION OF THE IMMUNE SYSTEM WITH IMMUNOSTIMULATING OLIGONUCLEOTIDES AND / OR IMMUNOMER COMPOUNDS RELATED TO CYTOKINES AND / OR CHEMOTHERAPEAN MEDICAMENTS OR RADIATION THERAPY
|
|
CA2536139A1
(en)
*
|
2003-09-25 |
2005-04-07 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid-lipophilic conjugates
|
|
KR101268877B1
(ko)
|
2004-09-01 |
2013-05-31 |
다이나박스 테크놀로지 코퍼레이션 |
선천성 면역반응 및 자가면역의 억제를 위한 방법 및조성물
|
|
LT2056845T
(lt)
|
2006-08-08 |
2017-11-27 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
5` fosfato oligonukleotidų struktūra ir panaudojimas
|
|
WO2009014887A2
(en)
*
|
2007-07-09 |
2009-01-29 |
Idera Pharmaceuticals, Inc. |
Stabilized immune modulatory rna (simra) compounds
|
|
AU2008317261B2
(en)
|
2007-10-26 |
2015-04-09 |
Dynavax Technologies Corporation |
Methods and compositions for inhibition of immune responses and autoimmunity
|
|
EP2207787B1
(en)
*
|
2007-11-06 |
2014-11-12 |
AdiuTide Pharmaceuticals GmbH |
Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
|
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
CA2752694A1
(en)
*
|
2009-02-10 |
2010-08-19 |
Idera Pharmaceuticals, Inc. |
Synthetic rna-based agonists of tlr7
|
|
KR101141544B1
(ko)
|
2009-03-13 |
2012-05-03 |
한국과학기술원 |
에스아이알엔에이 다중 접합체 및 이의 제조방법
|
|
PL2411521T3
(pl)
|
2009-03-25 |
2015-08-31 |
Univ Texas |
Kompozycje do stymulacji wrodzonej odporności immunologicznej na patogeny u ssaków
|
|
DK2470656T3
(da)
*
|
2009-08-27 |
2015-06-22 |
Idera Pharmaceuticals Inc |
Sammensætning til hæmning af genekspression og anvendelser heraf
|
|
WO2011159958A2
(en)
|
2010-06-16 |
2011-12-22 |
Dynavax Technologies Corporation |
Methods of treatment using tlr7 and/or tlr9 inhibitors
|
|
CA2802721C
(en)
*
|
2010-06-25 |
2015-08-18 |
Idera Pharmaceuticals, Inc. |
Novel agonists of toll-like receptor 3 and methods of their use
|
|
US8877722B2
(en)
|
2011-03-25 |
2014-11-04 |
Idera Pharmaceuticals, Inc. |
Compositions for inhibiting gene expression and uses thereof
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
US9844592B2
(en)
|
2011-07-18 |
2017-12-19 |
Icahn School Of Medicine At Mount Sinai |
Bacterial RNAs as vaccine adjuvants
|
|
BR112014011896B1
(pt)
|
2011-11-18 |
2021-01-19 |
Alnylam Pharmaceuticals, Inc. |
Agentes de rnai, composições, método de inibição de expressão de uma transtirretina(ttr), uso destes agentes, e kits
|
|
CN108977446A
(zh)
|
2011-11-18 |
2018-12-11 |
阿尔尼拉姆医药品有限公司 |
修饰的RNAi试剂
|
|
WO2013117348A1
(en)
*
|
2012-02-09 |
2013-08-15 |
Carsten Kirschning |
Agonists and antagonists of toll-like receptor (tlr) 13
|
|
WO2014022739A2
(en)
|
2012-08-03 |
2014-02-06 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
US9228184B2
(en)
|
2012-09-29 |
2016-01-05 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
US9868955B2
(en)
|
2012-09-29 |
2018-01-16 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
ES2657608T3
(es)
|
2012-12-05 |
2018-03-06 |
Alnylam Pharmaceuticals, Inc. |
Composiciones de arni de pcsk9 y métodos de uso de las mismas
|
|
WO2014110081A1
(en)
*
|
2013-01-08 |
2014-07-17 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
|
|
PT2970974T
(pt)
|
2013-03-14 |
2017-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de componente do complemento c5 e métodos para a sua utilização
|
|
EP2999785B1
(en)
|
2013-05-22 |
2018-04-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 irna compositions and methods of use thereof
|
|
KR102365809B1
(ko)
|
2013-05-22 |
2022-02-23 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 조성물 및 이의 사용 방법
|
|
WO2015042564A1
(en)
|
2013-09-23 |
2015-03-26 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing transthyretin (ttr) associated diseases
|
|
EA201691215A1
(ru)
|
2013-12-12 |
2016-11-30 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA К КОМПОНЕНТУ КОМПЛЕМЕНТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
WO2015106128A2
(en)
|
2014-01-09 |
2015-07-16 |
Alnylam Pharmaceuticals, Inc. |
MODIFIED RNAi AGENTS
|
|
EP3960860A3
(en)
|
2014-02-11 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
CA2968114A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
|
EP3234141A4
(en)
|
2014-12-18 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
IL316159A
(en)
|
2015-06-15 |
2024-12-01 |
Mpeg La Llc |
Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
|
|
DE102015008536A1
(de)
|
2015-07-02 |
2017-01-05 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Diskontinuierliche Oligonukleotid-Liganden
|
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
|
KR20250145703A
(ko)
|
2015-09-02 |
2025-10-13 |
알닐람 파마슈티칼스 인코포레이티드 |
프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
|
|
WO2017079983A1
(en)
*
|
2015-11-13 |
2017-05-18 |
Amoigen Bioscience (Xiamen) Company Limited |
USES OF MICRORNA MIR-574-5p-BASED COMPOUNDS AS IMMUNOMODULATORS AND COMPOSITIONS THEREOF
|
|
CA3007014A1
(en)
|
2015-12-07 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
|
WO2017136399A1
(en)
*
|
2016-02-02 |
2017-08-10 |
Idera Pharmaceuticals, Inc. |
POTENTIATION OF mmRNA THERAPEUTICS
|
|
JP2019518028A
(ja)
|
2016-06-10 |
2019-06-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法
|
|
CN106119357B
(zh)
*
|
2016-06-29 |
2019-09-10 |
北京泱深生物信息技术有限公司 |
Tns11在制备诊治子宫内膜癌产品中的应用
|
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
SG10201913552UA
(en)
|
2016-12-16 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
|
JP6792847B2
(ja)
*
|
2016-12-27 |
2020-12-02 |
国立大学法人 東京大学 |
mRNAの機能化方法
|
|
IL307726A
(en)
|
2017-02-06 |
2023-12-01 |
Mpeg La Llc |
Multimeric oligonucleotides with reduced renal clearance
|
|
US20200163987A1
(en)
|
2017-07-10 |
2020-05-28 |
Genzyme Corporation |
Methods and compositions for treating a bleeding event in a subject having hemophilia
|
|
EP3652317A1
(en)
|
2017-07-13 |
2020-05-20 |
Alnylam Pharmaceuticals, Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
|
EP3710587A1
(en)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
EP3714054A1
(en)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
BR112020012088A2
(pt)
|
2017-12-18 |
2020-11-17 |
Alnylam Pharmaceuticals, Inc. |
composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
|
|
BR112020022546A8
(pt)
|
2018-05-07 |
2022-05-17 |
Alnylam Pharmaceuticals Inc |
Entrega extra-hepática
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
|
JP2022500003A
(ja)
|
2018-09-18 |
2022-01-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
|
JP7470107B2
(ja)
|
2018-09-28 |
2024-04-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
トランスサイレチン(TTR)iRNA組成物及びTTR関連眼疾患を治療又は予防するためのその使用方法
|
|
US20220211743A1
(en)
|
2019-05-17 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
|
EP4007811A2
(en)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
|
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
|
IL292360A
(en)
|
2019-10-22 |
2022-06-01 |
Alnylam Pharmaceuticals Inc |
IRNA components c3 supplementary component and methods of using them
|
|
AU2020376840A1
(en)
|
2019-11-01 |
2022-04-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (HTT) iRNA agent compositions and methods of use thereof
|
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
CA3160329A1
(en)
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
CA3161703A1
(en)
|
2019-11-13 |
2021-05-20 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
TWI897902B
(zh)
|
2019-12-13 |
2025-09-21 |
美商阿尼拉製藥公司 |
人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法
|
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
JP2023514190A
(ja)
|
2020-02-10 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Vegf-a発現をサイレンシングするための組成物および方法
|
|
AU2021224778A1
(en)
|
2020-02-18 |
2022-09-29 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
AU2021232014A1
(en)
|
2020-03-06 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) IRNA compositions and methods of use thereof
|
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
JP2023519274A
(ja)
|
2020-03-26 |
2023-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
コロナウイルスiRNA組成物およびその使用方法
|
|
WO2021202443A2
(en)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
US12534731B2
(en)
|
2020-04-01 |
2026-01-27 |
Alnylam Pharmaceuticals, Inc. |
Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
|
|
AR121769A1
(es)
|
2020-04-06 |
2022-07-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para el silenciamiento de la expresión de myoc
|
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
|
BR112022020227A2
(pt)
|
2020-04-07 |
2022-11-22 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciamento da expressão de scn9a
|
|
JP2023523993A
(ja)
|
2020-04-27 |
2023-06-08 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
アポリポタンパク質E(ApoE)iRNA剤組成物およびその使用方法
|
|
AU2021265813A1
(en)
|
2020-04-30 |
2022-11-10 |
Alnylam Pharmaceuticals, Inc. |
Complement factor B (CFB) iRNA compositions and methods of use thereof
|
|
US20230348903A1
(en)
*
|
2020-05-19 |
2023-11-02 |
Hudson Institute of Medical Research |
Oligonucleotides
|
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
|
CN116075592A
(zh)
|
2020-06-09 |
2023-05-05 |
阿尔尼拉姆医药品有限公司 |
用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
|
|
WO2021252557A1
(en)
|
2020-06-09 |
2021-12-16 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
IL299063A
(en)
|
2020-06-18 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Xanthine dehydrogenase (xdh) RNA compositions and methods of using them
|
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
TW202229552A
(zh)
|
2020-10-05 |
2022-08-01 |
美商艾拉倫製藥股份有限公司 |
G蛋白-偶合受體75(GPR75)iRNA組成物及其使用方法
|
|
AU2021365822A1
(en)
|
2020-10-21 |
2023-06-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
EP4244355A1
(en)
|
2020-11-13 |
2023-09-20 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor v (f5) irna compositions and methods of use thereof
|
|
CA3201452A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
AU2021411579A1
(en)
|
2020-12-31 |
2023-07-13 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
|
WO2022147223A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
MX2023009324A
(es)
|
2021-02-12 |
2023-10-13 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni de superóxido dismutasa 1 (sod1), y métodos de uso de este para el tratamiento o prevención de enfermedades neurodegenerativas relacionadas con superóxido dismutasa 1 (sod1).
|
|
EP4298220A1
(en)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods of use thereof
|
|
CA3211059A1
(en)
|
2021-02-26 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
IL305414A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
KR20230162024A
(ko)
|
2021-03-29 |
2023-11-28 |
알닐람 파마슈티칼스 인코포레이티드 |
헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법
|
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
WO2022231999A1
(en)
|
2021-04-26 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法
|
|
JP2024522068A
(ja)
|
2021-05-18 |
2024-06-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法
|
|
TW202317762A
(zh)
|
2021-06-02 |
2023-05-01 |
美商艾拉倫製藥股份有限公司 |
含有類PATATIN磷脂酶結構域3(PNPLA3)的iRNA組成物及其使用方法
|
|
KR20240017911A
(ko)
|
2021-06-04 |
2024-02-08 |
알닐람 파마슈티칼스 인코포레이티드 |
인간 염색체 9 개방 해독 프레임 72(C9orf72) iRNA 제제 조성물 및 이의 사용 방법
|
|
JP2024523000A
(ja)
|
2021-06-08 |
2024-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シュタルガルト病及び/又は網膜結合タンパク質4(rbp4)関連障害を治療又は予防するための組成物及び方法
|
|
IL309296A
(en)
|
2021-06-30 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
|
|
JP2024527584A
(ja)
|
2021-07-09 |
2024-07-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
CNS送達のためのBis-RNAi化合物
|
|
TW202333748A
(zh)
|
2021-07-19 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
|
|
CN117716032A
(zh)
|
2021-07-21 |
2024-03-15 |
阿尔尼拉姆医药品有限公司 |
代谢病症相关靶基因iRNA组合物和其使用方法
|
|
EP4373933A1
(en)
|
2021-07-23 |
2024-05-29 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
|
IL310244A
(en)
|
2021-08-03 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Transthyretin (TTR) IRNA compositions and methods of using them
|
|
MX2024001445A
(es)
|
2021-08-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) y metodos para silenciar el angiotensinogeno (agt).
|
|
TW202334413A
(zh)
|
2021-08-13 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
第十二因子(F12)iRNA組成物及其使用方法
|
|
MX2024002440A
(es)
|
2021-08-31 |
2024-03-08 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
|
|
EP4401742A2
(en)
|
2021-09-17 |
2024-07-24 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
|
KR20240083183A
(ko)
|
2021-09-20 |
2024-06-11 |
알닐람 파마슈티칼스 인코포레이티드 |
인히빈 서브유닛 베타 e (inhbe) 조절제 조성물 및 이의 이용 방법
|
|
EP4405484A2
(en)
|
2021-09-24 |
2024-07-31 |
Alnylam Pharmaceuticals, Inc. |
Microtubule associated protein tau (mapt) irna agent compositions and methods of use thereof
|
|
CA3234887A1
(en)
|
2021-10-15 |
2023-04-20 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
|
WO2023076451A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
EP4469575A2
(en)
|
2022-01-24 |
2024-12-04 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
|
TW202424193A
(zh)
|
2022-09-15 |
2024-06-16 |
美商艾拉倫製藥股份有限公司 |
第13型17β-羥基類固醇去氫酶(HSD17B13)iRNA組成物及其使用方法
|
|
JP2025532985A
(ja)
|
2022-09-30 |
2025-10-03 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
修飾二本鎖rna剤
|
|
AU2024254919A1
(en)
|
2023-04-12 |
2025-10-30 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery of double-stranded rna agents
|
|
AU2024322388A1
(en)
|
2023-08-04 |
2026-01-22 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ctnnb1-associated disorders
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|